Biorestorative Therapies, INC DEF 14A proxy statements

BioRestorative Therapies is holding a special meeting on May 26, 2026, to vote on increasing authorized common stock from 75 million to 1.5 billion shares, aiming to fund clinical trials and general corporate needs.

BioRestorative Therapies, Inc. announces its Annual Meeting to address director elections, a stock incentive plan increase, auditor ratification, and executive compensation amidst ongoing net losses and declining shareholder returns.

BioRestorative Therapies is holding its annual meeting on September 19, 2024, to vote on the election of a director, an amendment to the stock incentive plan, and the ratification of its independent auditor.